Janice Pieretti, MD, FACC, explains why therapies for transthyretin amyloid cardiomyopathy deliver the most benefit before damage accrues.
Janice Pieretti, MD, FACC
Advertisement
Articles by Janice Pieretti, MD, FACC
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
3
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
4
Glucose Monitoring: Timing Makes Every Reading Count
5